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Cancer-associated glycan structures can be both tumor markers and engines of disease progression. 
The structure Siaα2,6Galβ1,4GlcNAc (Sia6LacNAc), synthesized by sialyltransferase ST6GAL1, is a 
cancer-associated glycan. Although ST6GAL1/Sia6LacNAc are often overexpressed in colorectal 
cancer (CRC), their biological and clinical significance remains unclear. To get insights into the clinical 
relevance of ST6GAL1 expression in CRC, we interrogated The Cancer Genome Atlas (TCGA) with 
mRNA expression data of hundreds of clinically characterized CRC and normal samples. We found 
an association of low ST6GAL1 expression with microsatellite instability, BRAF mutations and 
mucinous phenotype but not with stage, response to therapy and survival. To investigate the impact 
of ST6GAL1 expression in experimental systems, we analyzed the transcriptome and the phenotype 
of the CRC cell lines SW948 and SW48 after retroviral transduction with ST6GAL1 cDNA. The two 
cell lines display the two main pathways of CRC transformation: chromosomal instability and 
microsatellite instability, respectively. Constitutive ST6GAL1 expression induced much deeper 
transcriptomic changes in SW948 than in SW48 and affected different genes in the two cell lines. 
ST6GAL1 expression affected differentially the tyrosine phosphorylation induced by hepatocyte 
growth factor, the ability to grow in soft agar, to heal a scratch wound and to invade Matrigel in the 
two cell lines. These results indicate that the altered expression of a cancer-associated 
glycosyltransferase impacts the gene expression profile, as well as the phenotype, although in a 
cancer subtype-specific manner.   






























































Glycosylation is a fundamental post-translational protein modification, which undergoes profound 
changes in cancer (Dall'Olio et al. 2012; Pinho et al. 2015). Altered sialylation is one of the most 
relevant cancer-associated glycosylation changes and is mainly due to the altered expression of 
sialyltransferases (Dall'Olio et al. 2014). Sialyltransferase ST6GAL1, product of the ST6GAL1 
gene, is the only enzyme able to add sialic acid on the subterminal galactose residues of 
lactosaminic chains (Galβ1,4GlcNAc) of glycoproteins (Weinstein et al. 1987), resulting in the 
biosynthesis of Sia6LacNAc (Siaα2,6Galβ1,4GlcNAc) (Supplementary Fig. S IA). Sia6LacNAc is 
frequently found at the non-reducing termini of N-linked chains of glycoproteins and can be 
detected by the lectin from Sambucus nigra (SNA) (Shibuya et al. 1987). The increased expression 
of ST6GAL1 in colorectal cancer (CRC) tissues was formerly reported by our laboratory (Dall'Olio 
et al. 1989) and later confirmed by others (Lise et al. 2000; Petretti et al. 2000; Seales et al. 2005). 
Increased expression of ST6GAL1 and/or of its cognate Sia6LacNAc structure has been observed in 
a variety of other malignancies (reviewed in (Dall'Olio 2000; Dall'Olio et al. 2001; Dall'Olio et al. 
2014)) of epithelial (Fukushima et al. 1998; Jun et al. 2012; Schultz et al. 2016; Shah et al. 2008) 
and non-epithelial origin (Mondal et al. 2010; Skacel et al. 1991). The biological and clinical 
implications of ST6GAL1 up-regulation have been the focus of numerous experimental and clinical 
studies. Some clinical CRC investigations report a positive relationship between high ST6GAL1/
Sia6LacNAc and increased malignancy (Gessner et al. 1993; Lise et al. 2000; Vierbuchen et al. 
1995), although some show the opposite (Yamashita et al. 1995; Zhang et al. 2017). Experimental 
studies on CRC cell lines genetically manipulated to up- or downregulate ST6GAL1, indicate that 
this enzyme positively affects resistance to apoptosis (Swindall et al. 2011; Zhuo et al. 2008), drug 
resistance (Chang et al. 2018; Cui et al. 2018), radiation resistance (Lee et al. 2008; Lee et al. 
2010a; Lee et al. 2010b) and stemness (Cui et al. 2018; Swindall et al. 2013). However, in vivo 
growth (Chiricolo et al. 2006; Park et al. 2012) and metastasis (Jung et al. 2016) were found to be 
higher in the absence of ST6GAL1. In other cancers, ST6GAL1 was found to support an invasive 
phenotype according to several studies (Britain et al. 2017; Britain et al. 2018; Chakraborty et al. 
2018; Han et al. 2018; Jones et al. 2018; Meng et al. 2015; Schultz et al. 2016; Wang et al. 2015; 
Wei et al. 2016), but not by others (Antony et al. 2014; Dawson et al. 2004; Yamamoto et al. 1997; 
Yamamoto et al. 2001; Yen et al. 2015).This study was undertaken to clarify the role of ST6GAL1 
in CRC both in the clinic and in experimental systems. To this aim, we interrogated The Cancer 
Genome Atlas (TCGA) data portal, a public database containing the gene expression data of 
hundreds of clinically and molecularly characterized 
CRC fresh tumors. Second, we investigated the effect of ST6GAL1 expression on the phenotype and 
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gene expression of two CRC cells lines, which display the two main pathways of CRC transformation: 
chromosomal instability (CIN) and microsatellite instability (MSI).
Results
Survey of transcriptomic databases
The analysis of transcriptomic data of hundreds of CRC and normal specimens from TCGA database 
allowed to investigate the relationship between ST6GAL1 gene expression and clinical parameters. 
As shown in Fig. 1A and B, ST6GAL1 mRNA expression is variable among CRC specimens (A) but 
quite uniform in normal tissues (B). No relationship existed between ST6GAL1 expression and 
clinical stage (Fig. 1C), while a highly significant association was found between low ST6GAL1 
expression and high microsatellite instability (MSI-h) (Fig. 1D). We did not observe an association 
between ST6GAL1 expression and APC (Fig. 1E), TP53 (Fig. 1F) and KRAS (Fig. 1G) mutations, but 
we found a highly significant association between low ST6GAL1 expression and BRAF mutation (Fig. 
1H). Low ST6GAL1 was associated also with a mucinous phenotype (Fig. 1I), while no relationship 
existed between ST6GAL1 expression and response to therapy (Fig. 1J) or overall survival (Fig. 1K). 
To strength the relationship between ST6GAL1 expression and microsatellite status, a different cohort 
of 23 MSS and 16 MSI-h CRC cases was investigated by a different microarray technology (Ferracin 
et al. 2008). As reported in Fig. S I, the lower ST6GALI expression expressed by MSI-h cases is fully 
consistent with that observed in the TCGA cohort. Collectively, these data suggest an association of 
ST6GAL1 expression with specific CRC features, but not with general progression. In search of a 
gene expression signature associated with high or low ST6GAL1 expression, two cohorts including 
the patients in the 15% upper and 15% lower percentiles of ST6GAL1 mRNA level were compared. 
As shown in Table I, the two cohorts displayed completely different gene expression signatures. In 
fact, samples from the upper percentile showed up-regulation of a few genes, including two CEA-
related genes (CEACAM5 and CEACAM6) and CD24, whose products share a common involvement 
in cell adhesion. On the contrary, low ST6GAL1 patients displayed up-regulation of a number of genes 
involved in several cellular functions, including carbohydrate metabolism, regeneration and repair, 
protein synthesis, mucin production and cytoskeleton organization. In particular, three members of 
the cytokeratin family (KRT8, KRT18 and KRT19) displayed up-regulation in low ST6GAL1 
expressers. The high expression of genes related with mucin production in low ST6GAL1 patients is 
in line with the observation that mucinous cancers display low ST6GAL1 expression (Fig. 1I).
The impact of ST6GAL1 overexpression on the transcriptome is strongly cell-type specific
To establish whether and how the overexpression of ST6GAL1 affects colon cancer cells, we analyzed 
the global gene expression profile of SW48 and SW948 colon cancer cell lines, permanently 
transduced with human ST6GAL1 cDNA (SW948 ST and SW48 ST) (Malagolini et al. 2009) and 
their respective negative controls transduced with an empty vector (SW948 NC and SW48 NC). As 
shown in Supplementary Fig. S II, the negative controls of both cell lines lacked endogenous 
ST6GAL1 expression, as previously reported for their wild type counterparts (Dall'Olio et al. 1995). 
As a result of ST6GAL1 transduction, both SW948 ST and SW48 ST expressed the ST6GAL1 mRNA, 
protein and enzymatic activity and Sia6LacNAc on the cell membrane, as revealed by fluorescent 
SNA. SNA-lectin blot analysis (Fig. S II F) revealed that multiple glycoproteins of different 
molecular weights are over α2,6-sialylated in ST6GAL1-transduced SW48 cells. However, in SW948 
ST cells the level of over α2,6-sialylation appears to be lower.   These two cell lines were chosen 
because they lack endogenous ST6GAL1 expression and display the two main pathways of colon 
cancer transformation. In fact, SW48 cells exhibit microsatellite instability, while SW948 cells 
display chromosomal instability. The heat map graph shown in Fig. 2 revealed that in both cell lines 
groups of genes were up- or down-regulated by ST6GAL1 expression. However, the number of 
ST6GAL1-modulated genes was higher in SW948 than in SW48 cells. Supplementary Table S I shows 
pathways significantly enriched upon ST6GAL1 overexpression, according to Metacore Pathway 
Enrichment Analysis. We reported the pathways likely to be relevant in CRC in Table II. In SW948 
cells, these include WNT signaling, TGF-β-induced EMT and transcription of HIF-1 target genes. In 
SW48 cells, the number of putatively affected pathways was much lower, including the metabolism 
of steroid hormones, the ephrin receptors, and cytoskeleton remodeling. A more in-deep analysis of 
the function of the ST6GAL1-modulated genes in SW948 and SW48 cells was performed through a 
literature search (Supplementary Tables S II and S III) and their putative tumor promoting or tumor 
restraining role was marked with a red or green label, respectively. In SW948 ST cells, genes with a 
recognized CRC-promoting role (MYEOV, BST2, TGFB2, KLF13, KLF8, XIST, SCGB2A1, NRP2) 
and genes with a tumor restraining role in CRC (ZC3H13, STAT4, EDN2, CTF1, WNT4) displayed 
up-regulation. Numerous genes with a recognized role in other malignancies displayed up- or down-
regulation in SW948 ST cells. In SW48 ST cells, some CRC-promoting genes displayed down-
regulation (TMEM41A, INHHB, INPP4B, EPHA3, ASB4, NTRK2, MAP1B), while the CRC tumor-
restraining genes PCDH1 and MUC2 displayed up-regulation. Consistent with TCGA data, the 
expression of three members of the cytokeratin family (KRT14, KRT16, KRT17) was reduced in 
ST6GAL1 expressing SW48 cells. However, this effect, which suggests a possible inhibitory effect 
of ST6GAL1 on cytokeratin expression, was not observed in SW948 cells, nor on the genes encoding 
non-cytoskeletal keratins. In SW948 cells, the sum of putative tumor-promoting changes (up-
regulation of red-marked genes + down-regulation of green-marked genes) was similar with that of 
putative tumor-restraining changes (down-regulation of red-marked genes + up-regulation of green-
marked genes) (21 vs.19). On the contrary, in SW48 cells we counted 6 putative tumor-promoting 
changes vs. 24 putative tumor-restraining changes. Unexpectedly, none of the genes modulated in 
one cell line showed parallel modulation in the other. Altogether, these data indicate that the gene 
expression changes induced by ST6GAL1 overexpression are strong but cell line specific.
HGF-induced tyrosine phosphorylation is differentially modulated by ST6GAL1 in CRC cell lines. 
A way through which a glycosyltransferase could influence gene expression, is the modulation of the 
cell signaling triggered by growth factors. Owing to the well-known role of HGF in stimulating cell 
motility and migration through FAK phosphorylation (Lai et al. 2000), as a first sight into the 
mechanisms downstream of ST6GAL1 expression, we investigated the phosphorylation of tyrosine 
residues and in particular Tyr397 of FAK by Western blotting in the ST6GAL1-transduced and their 
negative control cell lines after HGF stimulation (Fig. 3). In unstimulated cells, Tyr397 
phosphorylation of FAK was significantly higher in SW948 ST than in SW948 NC (Fig. 3A). While in 
SW948 ST cells pFAK decreased progressively during HGF treatment, in SW948 NC it rose gradually 
during treatment time. A similar trend was observed on the most abundant Tyr phosphoproteins of 
125, 60 and 25 kDa Fig. 3A). On the other hand, treatment of SW48 NC and ST with HGF failed to 
induce significant changes of Tyr397 phosphorylation of FAK and of the 125, 60 and 25 kDa Tyr-
phosphoproteins (Fig. 3B). These results indicate that ST6GAL1 expression strongly affects HGF-
induced tyrosine phosphorylation and consequently HGF signaling in SW948 cells but not in SW48 
cells. 
The phenotype of colon cancer cells is differentially modulated by ST6GAL1 overexpression. 
To investigate the effect of ST6GAL1 expression on the malignant phenotype, SW48 and SW948 
cells transduced with the ST6GAL1 cDNA and their respective negative controls were assayed for 
key phenotypic features associated with malignancy. The ability to grow in a semi-solid medium, 
such as the soft agar (Fig. 4A), was differentially modulated by ST6GAL1 in SW948 and SW48. In 
fact, it resulted in the formation of fewer clones in the cell line SW948 and in a slightly increased 
number of clones in the cell line SW48. The time required to heal a scratch wound in a cell culture 
(Fig. 4B) was shorter for SW948 ST than for SW948 NC. This was largely due to the fact that SW948 
ST cells tend to proliferate first in monolayer and only successively as a multilayer, while SW948 
NC cells show a stronger tendency to multi-layer growth. On the contrary, SW48 NC cells closed the 
wound faster than SW48 ST cells. The ability to invade the extracellular matrix (Matrigel) was the 6





























































same in SW948 NC and ST, while it was strongly reduced in SW48 ST, compared with SW48 NC 
(Fig. 4C).
ST6GAL1 overexpression and stemness. 
To investigate the relationship between ST6GAL1 expression and stemness, we analyzed the four 
cells lines for the expression of known markers of stemness: aldehyde dehydrogenase (ALDH) and 
CD133. The first is reported to be a stem cell and a cancer-initiating cell marker in many tissues, 
including colon (Volonte et al. 2014) while the second is a surface protein associated with stemness 
in various cancers, including CRC (Ricci-Vitiani et al. 2007). In a typical experiment (Fig. 5A), 
cells were incubated with the ALDH substrate ALDEFLUOR, either in the presence or in the 
absence of DEAB (a specific ALDH inhibitor) for negative control. While the percentage of 
ALDH-positive cells was about 70% in the SW948 cell type, it was about-30-40% in the SW48 cell 
type. However, little and non-significant changes attributable to ST6GAL1 expression were 
observed. Flow cytometric analysis of CD133-labelled cells (Fig. 5B) revealed a slightly 
higher percentage of CD133+ and CD133+ high cells in the SW948 ST cell line, but no differences 
between SW48 NC and SW48 ST.
Discussion
To clarify the role of ST6GAL1 into the clinic, we correlated the ST6GAL1 mRNA expression with 
patients’ parameters using the TCGA database. The low level of ST6GAL1 mRNA we observed in 
high MSI patients in two different cohorts is consistent with a previous observation reporting that 
high SNA reactivity was correlated with MSS phenotype (Gebert et al. 2012). The association 
between low ST6GAL1 and BRAF mutation is consistent with the fact that BRAF is frequently mutated 
in MSI CRC patients. Although correlations have been reported in CRC between ST6GAL1 
expression and chemoresistance (Chang et al. 2018; Cui et al. 2018), metastasis formation (Gessner 
et al. 1993) and poor prognosis (Lise et al. 2000), TCGA data did not support an association between 
ST6GAL1 mRNA expression and clinical stage, response to therapy and overall survival.  Mutation 
or overexpression of RAS has been associated with ST6GAL1 overexpression in different cultured cell 
types (Dalziel et al. 2004; Seales et al. 2003), but the level of ST6GAL1 mRNA was not higher in 
KRAS mutated specimens. The high ST6GAL1-expressing tumors displayed mainly high levels of the 
transcripts of CEACAM5 and CEACAM6, two cell adhesion molecules of the CEA family promoting 
invasion and metastasis in vitro (Blumenthal et al. 2005).  On the other hand, low ST6GAL1-
expressing cases displayed up-regulation of a variety of genes involved in key features of malignancy, 
including carbohydrate metabolism, tissue repair, protein synthesis, cytoskeleton organization, and 
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mucin secretion. These associations do not necessarily imply a causal relationship between the 
expression of ST6GAL1 and that of other genes. To study the causal effect of ST6GAL1 
overexpression on transcriptome modulation in different cellular contexts, we transduced with the 
ST6GAL1 cDNA two cell lines, displaying the two main types of genomic instability in CRC. 
ST6GAL1-expressing cells exhibited higher α2,6-sialylation of different molecular weight proteins, 
although the effect on protein α2,6-sialylation appeared to be more pronounced in SW48 cells than in 
SW948 cells. On the other hand, the impact of ST6GAL1 on the transcriptome was stronger in 
SW948 than in SW48 cells. In fact, while in the MSS SW948 cells the expression of ST6GAL1 
modulated numerous genes, a large number of which were putatively involved in cancer, in the MSI 
SW48 cell line only a few cancer-related genes displayed modulation. Notably, no genes revealed 
parallel and consistent ST6GAL1-induced modulation in the two cell lines, indicating that the 
influence of a glycosyltransferase on the transcriptional activity depends on the cellular context. A 
partial explanation for the differential transcriptomic response induced by ST6GAL1 in the two cell 
lines can be provided by the differential ability of ST6GAL1 to modulate the response to growth 
factors, as we documented for HGF. 
Some phenotypic aspects of transduced cells could be explained by the transcriptional changes 
induced by ST6GAL1. For example, TGFB and WNT signaling predicted to be affected by ST6GAL1 
expression in SW948 cells, could be responsible for the different ability to grow in soft agar and to 
heal a wound displayed by SW948 ST cells. Interestingly, while we show here that sialylation can 
affect TGFB expression, several lines of evidence show that TGFB signaling strongly impacts cell 
glycosylation and in particular sialylation (Lee et al. 2013; Lee et al. 2015; Lee et al. 2016). The 
increased ability to heal a scratch wound displayed by SW948 ST may depend both on their reduced 
ability to multilayer growth and from increased migration. This latter ability can be related to 
MYEOV overexpression, as documented for another CRC cell line (Lawlor et al. 2010). Regarding 
SW48 cells, the general ST6GAL1-induced down-regulation of MAP1B and of cytokeratin genes, 
which are involved in migration and cytoskeletal organization, could explain the reduced ability of 
SW48 ST to invade Matrigel. Altogether, these data indicate that the impact of ST6GAL1 
expression on gene expression is potentially able to modulate multiple cancer-related cellular 
functions. 
Other sialyltransferases have recently been shown to modulate transcriptional activity of cancer cell 
lines (Severino et al. 2017; Severino et al. 2018). This points to the mechanisms through which a 
glycosyltransferase, that encodes an enzyme acting mainly on membrane and secreted glycoproteins, 
can affect gene transcription. The most plausible mechanism implies that differentially glycosylated 
membrane receptors modulate signal transduction cascades (Gomes Ferreira et al. 2018), which 
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ultimately affect the transcription factor activity and the epigenetic pattern (Dall'Olio et al. 
2017). Thus, the evident phenotypic changes in ST6GAL1-expressing cells can be explained by two 
partially overlapping mechanisms: a direct modulation of cell membrane receptors (for example the 
strength of integrin binding) and an indirect mechanism, through modulation of gene 
expression, which impacts multiple functions. Current results show that, whatever the changes 
induced by ST6GAL1 expression in colon cancer cells, they are strongly cell-type specific, ruling 
out the possibility that the association of ST6GAL1 and malignancy is a general paradigm. 
This should be kept into consideration for every future use of ST6GAL1 as a molecular target.
Materials and Methods
Analysis of transcriptomic databases 
Gene expression data and clinical information for 623 colorectal adenocarcinoma samples and 
51 normal tissues were downloaded from TCGA database using Firebrowse 
website (http://firebrowse.org).   RSEM normalized data for colon adenocarcinoma 
(COADREAD) cohort were matched with clinical data from Clinical Pick Tier1 archive. Mutations 
for these patients were retrieved using cBioPortal web site http://www.cbioportal.org. ST6GAL1 
mRNA expression was compared with stage, MSI status, response to treatment, histological type, 
survival, and KRAS, BRAF, APC and TP53 mutations. Since the samples did not present a 
normal distribution of ST6GAL1 expression, non-parametric statistical tests were used. Mann 
Whitney test was used to analyze the difference of ST6GAL1 expression in normal and tumor 
tissues, mucinous vs. non-mucinous histological type, and in KRAS, BRAF, APC or TP53 mutated 
vs. wild type patients. Kruskal-Wallis test was used to evaluate ST6GAL1 mRNA expression 
across cancer stages and MSS/MSI groups. The survival curve was estimated by the Kaplan-Meier 
method and the Mantel-Cox log-rank test was performed to test differences between the survival 
curves. Identification of highly expressed genes in the high and low ST6GAL1 expressers was 
performed through two-way ANOVA and Sidak's test for multiple comparisons. Gene expression in 
a different cohort of CRC cases (Ferracin et al. 2008) was analyzed by Agilent Technologies, and 
ST6GAL1 expression level was correlated with MSS or MSI-h status. 
Cell lines 
SW948 (ATCCR Number: CCL-237™) and SW48 (ATCCR Number: CCL-231™) cell line 
were cultured in Leibovitz's L-15 Medium in absence of CO2 (L-15 is phosphate buffered) in a 
humidified incubator. Details on the lentiviral transduction with human ST6GAL1 cDNA (ST cells) 
or with an empty vector (NC cells) were reported previously (Malagolini et al. 2009). Cell lines 
were genotyped 






























































by using highly-polymorphic short tandem repeat loci, which were amplified using the PowerPlex® 
16 HS System (Promega). Fragment analysis was done on an ABI3730xl (Life Technologies) and 
the resulting data were analyzed with GeneMarker HID software (Softgenetics) by 
Microsynth (Switzerland). Reports are available on request.
Transcriptomic analysis 
Transcriptomic analysis of RNA from SW948 and SW48 NC and ST RNA was performed in 
duplicate using Agilent whole human genome oligo microarray (G4851A) as described (Ferracin et 
al. 2013). Statistical analysis was performed using two-way ANOVA for repeated measures and the 
false discovery rate was controlled with two-stage linear step-up procedure of Benjamini, Krieger 
and Yekutieli with Q=0.05. Pathway analysis of differentially expressed genes was determined using 
the web-based software MetaCore (GeneGo, Thomson Reuters). Gene function was studied through 
an extensive literature search.  
Real-Time PCR 
Total RNA was extracted according to Chomczynski e Sacchi (Chomczynski et al. 1987) and reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
following manufacturer’s instructions. The PCR reaction was carried out in triplicate with 20 ng 
cDNA, with TaqMan Fast Universal PCR Master Mix (Applied Biosystems), TaqMan probes for 
ST6GAL1 (assay identification Hs00949382_m1) or ACTB (Hs99999903_m1) in a final volume of 
10 μL.
HGF treatment 
SW948 and SW48 NC and ST cells were plated at a concentration of 2 x 106 per well in a 6 
multiwell plate, let adhere for 24-48 hours, serum-starved for 24 hours and treated with HGF at a 
final concentration of 25 ng/mL, for 15, 30 or 120 minutes. Cells were lysed for 15 minutes in ice 
with Ripa Buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1%NP-40, 0.5% DOC, 0.1% SDS 
supplemented with protease inhibitor and phosphatase inhibitor cocktail). 
Western and SNA blot analysis 
Equal amounts of proteins were electrophoresed according to Laemmli protocol in 8% acrylamide 
gels (or 6% for SNA-blot analysis) in denaturing and reducing conditions and blotted to activated 
PVDF membranes. Membranes were blocked for 1 hour at room temperature with 1.5% BSA in 
Tris-buffered saline and 0,05% Tween20 (TBS-T), then incubated overnight at 4°C with primary 






























































antibody. After washing with TBS-T, membranes were incubated for 1 hour at room temperature 
with a secondary antibody conjugated with horseradish peroxidase (HRP). Detection was 
performed using Super Signal West Pico as a chemiluminescent substrate. Densitometric analysis 
was performed using Kodak 1D software and statistical analysis with two-way ANOVA followed 
by Holm-Sidak's multiple comparisons test. The following primary antibodies and lectins were 
used: mouse monoclonal anti-phosphotyrosine (Cytoskeleton) and anti-vinculin (Sigma), rabbit 
polyclonal anti-β-Actin (Sigma) and anti-FAK [pY397] (Life Technologies), goat polyclonal anti-
ST6GAL1 (R&D systems). Digoxigenin-conjugated SNA was as described (Malagolini et al. 
2009). As secondary antibodies, polyclonal rabbit anti-mouse (Sigma), goat anti-rabbit (Sigma), 
donkey anti-goat (R&D system) and anti-digoxigenin (Abcam) conjugated to HRP were used.  
Soft agar growth assay 
One mL/well of a 0.5% agar solution in complete L-15 was dispensed in each well of a 6 well plate 
and allowed to solidify. On the top of this layer of agar, one mL of a 0.3% agar solution in 
complete L-15 medium containing 1 x104 cells per well was dispensed in triplicate. The plates 
were incubated for two weeks at 37°C in a humidified incubator without CO2. To evaluate the 
number of colonies formed, the plates were fixed and colored for one hour with a solution 
containing formaldehyde 4%and crystal violet 0.005% in PBS. Pictures were taken at 4 X 
magnification and colonies were counted. Statistical analysis was performed using non-
parametric Kolmogorov-Smirnov test.
Wound healing assay 
The wound healing assay was performed using Culture-Insert 2 Well (Ibidi). Aliquots of 7x104 (for 
SW48) or 5x104 (for SW948) cells were seeded in each well. When the cells reached confluency, 
the insert was removed and healing of the wound was measured by taking pictures at 4 X 
magnification. The area free of cells was measured using the MRI Wound Healing 
Tool in ImageJ (http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Wound_Healing_Tool). 
Statistical analysis was performed using two-way ANOVA and Tukey's multiple comparisons test.
Transwell invasion assay 
The transwell invasion assay was performed using Matrigel-coated polycarbonate filters (8 µm 
pore size, Corning BioCoat Matrigel Invasion Chamber). Aliquots of 2x105 (for SW948) or 
4x105 (for SW48) of 24 hours-serum starved cells were seeded in the upper chamber of the well in 
serum-free medium. Complete L-15 with 10% FBS was placed as chemoattractant in the lower 
chamber of the well. The plates were then incubated for 24 hours at 37°C in a humidified 
incubator without CO2. Membranes were fixed in methanol, stained with toluidine blue, mounted 
on slides and cells were 






























































counted with a microscope at a 10 X magnification. Statistical analysis was performed by using 
two-way ANOVA and Sidak's multiple comparisons test.
Stemness analysis 
ALDEFLUOR (Stem Cell technologies) was activated following manufacturer’s instructions 
and added to 2 x 105 aliquots of cells. Half of the cell suspension was treated with DEAB, a 
specific ALDH inhibitor used for negative control. After 30 minutes at 37°C, cells were 
washed and suspended in ALDEFLUOR buffer. The fluorescent signal was acquired with a 
FACSCalibur flow cytometer and Cell Quest Pro software. On a dot plot with FL1 (green 
fluorescence) on the X axis and SSC on the Y axis, we set the fluorescence of the DEAB sample 
(negative control) and defined the area for ALDH positive cells. Cells included in this area were 
considered ALDEFLUOR positive. An aliquot of 3 x 105 cells was incubated with mouse 
monoclonal CD133/1 (AC133)-phycoerythrin antibody (Miltenyi Biotech) for 10 minutes at 4°C in 
the dark in the appropriate buffer (PBS pH 7.2, 0.5% BSA and 2 mM EDTA). After a wash, cells 
were analyzed by flow cytometry.
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Fig. I. Data from the TCGA database. A: ST6GAL1 mRNA expression in cancer tissues of CRC 
patients. B-J: box plot graphs showing median and Q1 and Q3 quartiles of ST6GAL1 mRNA 
expression in CRC and normal tissues (B); in CRC tissue of stage I-IV patients (C); in CRC tissue of 
patients with microsatellite stability (MSS), low grade microsatellite instability (MSI-l), high grade 
microsatellite instability (MSI-h) (D); in CRC tissue of patients with wild type or mutated APC (E), 
TP53 (F), KRAS (G), BRAF (H); with mucinous or non-mucinous phenotype (I); showing response 
or no-response to therapy (J). K: Survival curves of patients falling in the upper or lower 15% 
percentile of ST6GAL1 mRNA expression (93 cases). Mann Whitney test was used in B, E, F, G, H, 
I, J. Kruskal-Wallis test was used in C and D. The Mantel-Cox test was used in K. **** p≤0.0001
Fig. II. Heatmaps of gene expression of ST6GAL1-transduced SW948 and SW48 cells. The genes 
that are differentially expressed between ST6GAL1-transduced cells (ST) and respective negative 
control NC are reported. 1 and 2 refer to the two independent replicates. Genes (columns) and samples 
(rows) were grouped by hierarchical clustering (Manhattan correlation). High- and low- expression 
was normalized to the average expression across all samples. To analyze the differences between 
ST6GAL1-transduced and negative control cells the moderated t-test was used. Corrected p-value cut-
off: 0.15; multiple test correction used:Benjamini-Hochberg.
Fig. III. HGF-induced tyrosine phosphorylation in ST6GAL1-transduced SW948 and SW48
cells. Cells were treated with HGF for the indicated times, harvested as described in Materials and 
Methods and analyzed by Western blot for phosphorylation of Tyr397 of FAK (upper panels) or for 
phosphotyrosines in SW948 (A) or SW48 (B). The chemiluminescent signals were normalized with 
that of β-actin. Histograms on the right represent the mean±SD of three independent experiments. 
*p<0.05.
Fig. IV. Phenotypic characterization of ST6GAL1-transduced SW948 and SW48 cells. A: Soft 
agar growth. Mock- or ST6GAL1-transduced cells were seeded in soft agar and the number of the 
colonies was determined as described in Materials and Methods. Representative fields are shown on 
the left (original magnification 5 X). The total number of colonies is reported on the right. Statistical 
analysis was performed using non-parametric Kolmogorov-Smirnov test. B: Scratch wound test. A 
wound was made in a confluent cell layer, as described in Material and Methods. The healing of the 
wound was monitored by taking pictures at given time intervals. Representative fields, taken at the 
time of the wound (Day 0) or seven days later (Day 7), are shown at the top (original magnification 
10 X), while the percentage of free wound measured after seven days of healing is reported at the 
20
bottom. Statistical analysis was performed using two-way ANOVA and Tukey's multiple 
comparisons test. C: Matrigel invasion test. Cells were seeded in the upper chamber of the transwell 
in serum-free medium. Complete medium was placed in the lower chamber of the well as 
chemoattractant. The membranes were fixed, stained, mounted on slides and the cells were counted 
using a microscope at a 10 X magnification. Statistical analysis was performed using two-way 
ANOVA and Sidak's multiple comparisons test. Photographs show representative experiments. 
Histograms report mean±SD of three independent experiments. ** p<0.01; **** p<0.0001.
Fig. V. Stem cell markers in ST6GAL1-transduced SW948 and SW48 cells. A: Cells were 
incubated with ALDEFLUOR either in the presence or in the absence of DEAB, a specific ALDH 
inhibitor used for negative control, as described in Materials and Methods. A gate excluding the vast 
majority of the cells labelled in the presence of DEAB was set (upper panels). Cells included in the 
gate in the absence of DEAB, were considered to be ALDH-positive. Numbers indicate the 
percentage of ALDH positive cells ±SD in three independent experiments. B: Cells were treated with 
anti-CD133 antibodies as detailed in Material and Methods and FACS analyzed. Red: NC cells, Blue: 
ST cells. The numbers indicate the percentages of cells included in the sections CD133-, CD133+ and 
CD133+high. 






























































Table I. Genes up-regulated in high- or low ST6GAL1 expressers, according to TCGA database
Genes up-regulated in high ST6GAL1 expressers
Gene name Protein Functions Functional class
CD24 CD24 CD24 protein
Sialoglycoprotein cell adhesion molecule. Promotes 
adhesion and metastasis
CEACAM5 Carcinoembryonic Antigen Related Cell 
Adhesion Molecule 5
Member of the CEA family. Biomarker for 
gastrointestinal cancers. Promotes cell adhesion and 
metastasis.
CEACAM6 Carcinoembryonic Antigen Related Cell 
Adhesion Molecule 5
Member CEA family. Promotes cell adhesion and 
metastasis.
Cell adhesion
FTL Ferritin light chain
Iron storage
Iron metabolism
PYGB Glycogen Phosphorylase 
B
Catalyzes the rate-determining step in glycogen 
degradation Carbohydrate metabolism
Genes up-regulated in low ST6GAL1 expressers
PKM2 Muscle pyruvate kinase
Contributes to the control of glycolysis and is 





REG1A Regenerating family 
member 1α
Regenerating proteins are acute phase reactants, 
lectins, antiapoptotic or growth factors.
TFF3 Trefoil factor 3
Involved in the maintenance and repair of the intestinal 





RPLP0 Ribosomal protein lateral stalk subunit P0




Promotes the binding of aminoacyl-tRNA to the A-site 
of ribosomes during protein biosynthesis
EEF2 Eukariotic translation elongation factor 2
Member of the GTP-binding translation elongation 
factor family essential for protein synthesis
Protein synthesis Protein 
synthesis
SERPINA1 Serpin family A member 1
Serine protease inhibitor for elastase, plasmin, 
thrombin, trypsin, chymotrypsin, and plasminogen 
activator
Protease inhibitor
LYZ Lysozime Bacteriolytic and enhancer of the activity of immunoagents
Antimicrobial and immune 
function






























































HLA-C MHC class 1, C Presentation of foreign antigens to CD8+ lymphocytes
ACTB Actin beta Cytoskeleton component
ACTG1 Actin gamma 1 A cytoplasmic actin found in non-muscle cells
KRT18 Keratin 18 Member of the intermediate filament family. Partner of KRT8
KRT19 Keratin 19 Member of the intermediate filament family
KRT8 Keratin 8 Partner of KRT18 in intermediate filaments
ANXA2 Annexin A2 Involved in cell motility, organization of cytoskeleton and exocytosis
S100A6 S100 calcium binding protein A6
Indirectly plays a role in the reorganization of the actin 
cytoskeleton and in cell motility
Cytoskeleton
MUC2 Mucin 2, Oligomeric Mucus/Gel-Forming
Coats the epithelia of the intestines and other mucous 
membranes. Downreguled in IBDs
MUC5B Mucin 5B, Oligomeric Mucus/Gel-Forming
Gel-forming mucin that contributes to the lubricating 
and viscoelastic properties of mucus
AGR2




Required for MUC2 post-transcriptional synthesis and 
secretion. Proto-oncogene
CLCA1 loride Channel Accessory 1
Involved in chloride conductance and regulation of 
mucus production. Potential tumor suppressor. Induces 
MUC5AC
FCGBP Fc Fragment of IgG Binding Protein
May be involved in the maintenance of the mucosal 
structure as a gel-like component of the mucosa
Mucin-related
COL1A1 Collagen Type I Alpha 1 Chain
Pro-alpha1 chains of type I collagen Extracellular matrix
Statistical analysis was performed using Two-way ANOVA and Sidak's test for multiple 
comparisons.






























































Table II. CRC cellular pathways enriched by ST6GAL1 overexpression in SW948 and SW48 cells 
SW948
Pathways and cellular 
processes
Number of 
involved genes p value
Genes in the 
pathway
Up-regulation of IL-8 in CRC 2/32 0.0055 WNT4, WNT
TGF-β-dependent induction of EMT 
via SMADs 2/32 0.0065 TGF-β, TGF-β2
Modulation of Ca++ and K+ channels 
by Adenosine A1 receptor in signal 
transduction
2/43 0.0097 SUR1, Kir6.2
Cytoskeleton remodeling. Regulation 
of actin cytoskeleton nucleation and 
polymerization by Rho GTPases
2/46 0.011 FMNL1, DRF
Leptin signaling via PI3K-dependent 
pathway 2/47 0.011 SUR1, Kir6.2
TGF-β-dependent induction of EMT 
via MAPK 2/47 0.011 TGF-β, TGF-β2
Canonical WNT signaling pathway 
in CRC 2/66 0.022 WNT4, WNT
Transcription of HIF-1 targets 2/95 0.043 TGF-β2, SDF-1
SW48
Estradiol metabolism 3/42 0.0002 UGT2B11, UGT2B7, UGT2B28




Cytoskeleton remodelling 3/36 0.0044 Keratin 14,  Keratin 16, Keratin 17


































































Fig. I. Data from the TCGA database. A: ST6GAL1 mRNA expression in cancer tissues of CRC patients. B-J: 
box plot graphs showing median and Q1 and Q3 quartiles of ST6GAL1 mRNA expression in CRC and normal 
tissues (B); in CRC tissue of stage I-IV patients (C); in CRC tissue of patients with microsatellite stability 
(MSS), low grade microsatellite instability (MSI-l), high grade microsatellite instability (MSI-h) (D); in CRC 
tissue of patients with wild type or mutated APC (E), TP53 (F), KRAS (G), BRAF (H); with mucinous or non-
mucinous phenotype (I); showing response or no-response to therapy (J). K: Survival curves of patients 
falling in the upper or lower 15% percentile of ST6GAL1 mRNA expression (93 cases). Mann Whitney test 
was used in B, E, F, G, H, I, J. Kruskal-Wallis test was used in C and D. The Mantel-Cox test was used in K. 
**** p≤0.0001 
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Fig. II. Heatmaps of gene expression of ST6GAL1-transduced SW948 and SW48 cells. The genes that are 
differentially expressed between ST6GAL1-transduced cells (ST) and respective negative control NC are 
reported. 1 and 2 refer to the two independent replicates. Genes (columns) and samples (rows) were 
grouped by hierarchical clustering (Manhattan correlation). High- and low- expression was normalized to the 
average expression across all samples. To analyze the differences between ST6GAL1-transduced and 
negative control cells the moderated t-test was used. Corrected p-value cut-off: 0.15; multiple test 
correction used:Benjamini-Hochberg. 
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Fig. III. HGF-induced tyrosine phosphorylation in ST6GAL1-transduced SW948 and SW48 
cells. Cells were treated with HGF for the indicated times, harvested as described in Materials and Methods 
and analyzed by Western blot for phosphorylation of Tyr397 of FAK (upper panels) or for phosphotyrosines 
in SW948 (A) or SW48 (B). The chemiluminescent signals were normalized with that of β-actin. Histograms 
on the right represent the mean±SD of three independent experiments. *p<0.05. 
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Fig. IV. Phenotypic characterization of ST6GAL1-transduced SW948 and SW48 cells. A: Soft agar growth. 
Mock- or ST6GAL1-transduced cells were seeded in soft agar and the number of the colonies was 
determined as described in Materials and Methods. Representative fields are shown on the left (original 
magnification 5 X). The total number of colonies is reported on the right. Statistical analysis was performed 
using non-parametric Kolmogorov-Smirnov test. B: Scratch wound test. A wound was made in a confluent 
cell layer, as described in Material and Methods. The healing of the wound was monitored by taking pictures 
at given time intervals. Representative fields, taken at the time of the wound (Day 0) or seven days later 
(Day 7), are shown at the top (original magnification 10 X), while the percentage of free wound measured 
after seven days of healing is reported at the bottom. Statistical analysis was performed using two-way 
ANOVA and Tukey's multiple comparisons test. C: Matrigel invasion test. Cells were seeded in the upper 
chamber of the transwell in serum-free medium. Complete medium was placed in the lower chamber of the 
well as chemoattractant. The membranes were fixed, stained, mounted on slides and the cells were counted 
using a microscope at a 10 X magnification. Statistical analysis was performed using two-way ANOVA and 
Sidak's multiple comparisons test. Photographs show representative experiments. Histograms report 






























































mean±SD of three independent experiments. ** p<0.01; **** p<0.0001. 
190x275mm (200 x 200 DPI) 






























































Fig. V. Stem cell markers in ST6GAL1-transduced SW948 and SW48 cells. A: Cells were incubated with 
ALDEFLUOR either in the presence or in the absence of DEAB, a specific ALDH inhibitor used for negative 
control, as described in Materials and Methods. A gate excluding the vast majority of the cells labelled in the 
presence of DEAB was set (upper panels). Cells included in the gate in the absence of DEAB, were 
considered to be ALDH-positive. Numbers indicate the percentage of ALDH positive cells ±SD in three 
independent experiments. B: Cells were treated with anti-CD133 antibodies as detailed in Material and 
Methods and FACS analyzed. Red: NC cells, Blue: ST cells. The numbers indicate the percentages of cells 
included in the sections CD133-, CD133+ and CD133+high. 
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